Use of Skull Vibration-Induced Nystagmus in the Follow-up of Patients With Ménière Disease Treated With Intratympanic Gentamicin

Article information

Clin Exp Otorhinolaryngol. 2023;16(3):236-243

Publication date (electronic) : 2023 June 26

doi : https://doi.org/10.21053/ceo.2023.00129

Susana Marcos Alonso, Nicole Almeida Ayerve, Chiara Monopoli Roca, Guillermo Coronel Touma, Juan Carlos del Pozo de Dios, Hortensia Sánchez Gómez, Santiago Santa Cruz Ruíz, Ángel Batuecas Caletrío

Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain

Corresponding author: Susana Marcos Alonso Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), University of Salamanca, Sevilla, 33, Villares de la Reina, Salamanca, Spain Tel: +34-648523084, Email: susana.ma.95@gmail.com

Received 2023 January 31; Revised 2023 May 27; Accepted 2023 June 24.

Abstract

INTRODUCTION

Ménière disease (MD) is an idiopathic disorder that impacts hearing and inner ear balance. This disease is marked by episodes of vertigo, a sensation of fullness in the ear, tinnitus, and fluctuating hearing loss. It is thought to be associated with anatomical changes in the inner ear, specifically an increase in the volume of endolymph (the fluid that fills the membranous labyrinth) and a decrease in the volume of perilymph (the fluid that surrounds the membranous labyrinth and fills the bony labyrinth). This shift in the fluid dynamics of the inner ear is referred to as endolymphatic hydrops [1]. The most common treatments for MD involve dietary changes such as a low-salt diet and limited intake of stimulants like caffeine, as well as the administration of systemic or intratympanic corticosteroids. The prevalence of MD ranges from 39 to 190 patients per 100,000 people [2], with 35% and 47% of cases presenting bilaterally over 10 and 20 years, respectively [3].

Intratympanic gentamicin (ITG) is recognized as an effective treatment for uncontrolled MD characterized by persistent vertigo attacks despite ongoing therapy [4,5]. The primary reasons for employing ITG to manage these episodes are its vestibulotoxic effect and its relatively lesser damage to cochlear function compared to other aminoglycosides [6]. The action mechanism of ITG is rooted in its interaction with the peripheral vestibular receptor and its capacity to decrease the gain of the vestibulo-ocular reflex (VOR) for each semicircular canal in the affected ear [7].

The video head impulse test (vHIT) is used to gauge the velocity of the eye during high-frequency and high-velocity cephalic impulses on a specific semicircular canal plane. This allows for the assessment of each canal as an individual entity, enabling the measurement of the angular VOR (aVOR) within its physiological range. Additionally, the vHIT captures refixation saccades that were either unobserved (covert) or observed (overt) when the aVOR was hypofunctional or failed to meet the requirements for head acceleration [8].

vHIT is a validated method for evaluating the function of semicircular canals following ITG application [9]. The relationship between the gain difference in the aVOR of the semicircular canals and the likelihood of a vertigo attack after ITG treatment has been previously established. Therefore, an increase in the gain of the affected ear and a smaller gain difference suggest a higher likelihood of recurrent vertigo attacks and repeated need for ITG [10]. The gain on the affected side is known to deteriorate during the initial 4 weeks of ITG administration. This decrease in gain between 3 and 4 weeks after ITG application may be attributed to the time required for gentamicin to move from the middle to the inner ear, delayed drug clearance, and the gradual progression of cellular damage [11]. In vHIT, a quantity termed the PR score can also be analyzed. Two types of saccades are possible: covert (refixation movements occurring during the head impulse) and overt (those occurring after the head movement has concluded). The saccades signify vestibular recovery, with the level of organization of the response indicating the degree of recovery. In other words, the more overt saccades take place, the less vestibular compensation is present. The PR score is the outcome of an algorithm that assigns a numerical value to the grouping of the saccades. It is based on the coefficient of variation measured at the peak velocity of the eyes. All ocular responses to all impulses recorded in the same trial are calculated. This provides a value between 0 and 100, with values closer to 0 indicating less saccade dispersion [12].

Assessment of skull vibration-induced nystagmus (SVIN) is another method for evaluating vestibular function. This reliable, noninvasive test is simple to administer and can be used to identify the affected side in cases of vestibular deficits, even in chronic and compensated pathologies. It can expose vestibular asymmetry and serves as a vestibular Weber test. The optimal stimulation frequency for this test is 100 Hz [13]. SVIN primarily induces a horizontal nystagmus that beats towards the healthy side in patients with a unilateral vestibular deficit [14]. A direct linear relationship has been observed between the slow-phase velocity (SPV) of SVIN using a 100-Hz skull vibrator and the gain difference (healthy ear/affected ear) as measured on vHIT [15].

The objective of this study was to identify any potential correlation between the SPV of SVIN and the recovery of vestibular function following ITG. Furthermore, we sought to determine whether the SVIN could potentially predict the onset of new vertigo episodes in patients with MD who have undergone ITG treatment.

MATERIALS AND METHODS

RESULTS

Group comparison

This descriptive frequency study included a study population of 88 patients with definite MD who were treated with ITG. The average age of the patients experiencing vertigo attacks (group A) was 55 years, while that of patients without such episodes (group B) was 59 years (Table 1). The statistical analyses revealed no significant associations between groups regarding sex, age, affected side, prior use of intratympanic corticoids, number of ITG injections, or Tumarkin crises.

Table 1.

Sample analysis

Video head impulse test

Statistically significant correlations (P<0.05) were observed between the gain on the affected side and the gain difference between the healthy and affected sides, and the PR score after 6 months and throughout the follow-up period (Table 1). The differences in gain between the healthy and affected ears at 6 months, presented as mean±standard deviation, were 0.59±0.05 in group A and 0.52±0.08 in group B. Subsequent follow-up assessments revealed gain differences of 0.16±0.06 in group A and 0.34±0.06 in group B. Of the 18 patients in group A, 15 exhibited gain recovery in the affected ear. However, none of the 70 patients in group B demonstrated recovery in the gain of the affected ear (Fig. 1).

Fig. 1.

Box and whisker plots. In the group that did not experience vertigo attacks after intratympanic gentamicin (“no”, group B), no change was noted in the gain on the affected side over time (A), nor was any change observed in the slow-phase velocity (SPV) (B). The SPV modification percentage remained close to 0% (C). Conversely, among those who did experience subsequent attacks (“yes”, group A, blue), the SPV decreased by 37% (C), the gain on the affected side recovered (A), and the SPV also decreased (B). For all patients in group A, the gain difference decreased because the gain on the affected side recovered in every case. The SPV also decreased in all patients in group A. VIN, vibration-induced nystagmus.

Video head impulse test vs. skull vibration-induced nystagmus

A positive correlation was observed between the changes in SPV on the affected side during follow-up and the gain on the same side (Pearson correlation coefficient, 0.6; P=0.000). A statistically significant relationship was found between the gain difference during follow-up and the change in SPV (P=0.000; Pearson correlation coefficient, 0.7). A linear regression model using these variables demonstrated a positive linear relationship. We observed a progressive linear relationship, with a Pearson correlation coefficient of 0.6 (P=0.000), of SPV and its changes with PR. The linear regression model that compared the changes in SPV and the difference in gain during follow-up revealed a linear relationship (Fig. 2).

Fig. 2.

Linear regression model. The blue dots denote patients who experienced vertigo attacks following intratympanic gentamicin (ITG) (“yes”, group A), while the green dots represent those who did not (“no”, group B). (A) As the gain in the affected ear increases, the slow-phase velocity (SPV) decreases (as evidenced by the predominance of blue dots in the lower right quadrant). This demonstrates a correlation between the SPV of the diseased side and the gain on that same side during follow-up (post-ITG). The Pearson correlation coefficient was 0.6, with a P-value of 0.000. (B) In the blue group, as the gain in the diseased ear recovered and the disparity in gains between both ears diminished, the SPV exhibited a greater percentage of change. In other words, it slowed down compared to the pre-crisis SPV. However, in the green group, the SPV remained unchanged. The Pearson correlation coefficient was 0.7, with a P-value of 0.000. VIN, vibration-induced nystagmus.

We utilized a logistic regression model to examine the correlation between the occurrence of vertigo crises following ITG administration and several variables: SPV on the affected side, alterations in SPV, gain on the affected side, and discrepancies between gains. A statistically significant relationship (P<0.01) was identified between these variables and the incidence of crises post-ITG administration.

DISCUSSION

SVIN assessment is a straightforward clinical test that involves applying a vibrator with a frequency of 100 Hz and moderate intensity, roughly equivalent to a body massager, to either mastoid of a patient suffering from total unilateral vestibular loss. This induces a primarily horizontal nystagmus, with clinically evident rapid phases moving away from the affected side [13]. The nystagmus stops immediately once the vibration is removed, with no subsequent nystagmus observed. Video recordings reveal that the nystagmus consists of SPV deviations away from the healthy ear, interspersed with quick return phases directed away from the affected ear [25]. These rapid phases can be easily detected by a clinician at the bedside using Frenzel glasses, although quantifying SPV necessitates three-dimensional recordings. Interestingly, with SVIN, the direction of the nystagmus remains the same regardless of which mastoid is stimulated. However, when the same procedure is performed on healthy individuals, it does not consistently induce nystagmus with an SPV greater than 2.5°/sec [13].

The clinical interpretation of these findings can be summarized as follows: an SVIN at 100 Hz, with the same direction when both mastoids are stimulated, suggests an asymmetry in the function of the semicircular canals between the two labyrinths. The fast phase points to the labyrinth with diminished function [26]. Three-dimensional recordings [13] have demonstrated that when mastoid vibration is applied to patients with a unilateral vestibular deficit, the SVIN exhibits a horizontal and torsional component directed towards the side of the healthy ear. Furthermore, evidence suggests that mastoid vibration simultaneously activates all semicircular canals and otoliths [27].

Recordings of vestibular afferents in guinea pigs have demonstrated that a 100-Hz vibration effectively stimulates both the semicircular canals and otolithic organs, resulting in irregular resting discharges. These discharges are termed “irregular” due to the variability in the interval between action potentials in these neurons when no stimulation is present (that is, during the resting discharge). These irregular afferents innervate the amphora-shaped type I receptors located in the crista crest or striola of the otolithic maculae [28]. Notably, however, gentamicin exhibits a predilection for ototoxicity in type I hair cells (HC-I) [29]. The relationship between the SPV measurement of the SVIN and the disparity in gain (healthy side versus affected side) as determined by the vHIT has been previously documented [15]. In patients with a unilateral vestibular deficit, the test has a sensitivity of 98%. However, it yields negative results in patients exhibiting hypoexcitability on the healthy side, as measured by the caloric test [30].

The findings from this study support the observed decrease in gain measured by the vHIT following gentamicin injection. They also highlight the correlation between gain recovery and the increase in the PR score on the affected side, as well as the recurrence of vertigo attacks. When patients exhibit ungrouped saccades, the PR score increases, indicating vestibular decompensation in those who experience recurring vertigo attacks. In contrast, in the group without recurrent episodes, the PR score decreased, suggesting vestibular compensation and a lower likelihood of vertigo recurrence [12]. Previous research has shown that the frequency of recurring episodes is significantly lower if the VOR gain has been reduced by less than 33% from the baseline after the first application of ITG [31]. This underscores the importance of monitoring VOR changes in patients undergoing ITG treatment. vHIT serves as a practical and straightforward tool for this purpose. In contrast, several studies have confirmed the spontaneous regeneration of the vestibular system following ototoxic damage in mammals [32]. Additionally, histological studies have shown the spontaneous regeneration of hair cells after ITG [33].

The findings of our study are consistent with previous research. However, we also discovered that monitoring the SPV in SVIN can be as beneficial as measuring VOR gains with vHIT. Specifically, in patients with MD treated with ITG who experienced new vertigo episodes, the gain in the affected ear was restored in 15 of 18 cases. Moreover, the SPV of the SVIN had decreased before the crisis in all 18 cases. This could suggest that SVIN is particularly sensitive and highly valuable for predicting the recurrence of vertigo attacks in MD after treatment with ITG.

The increased sensitivity of the SPV of SVIN compared to vHIT in patients experiencing vertigo crises could be attributed to the fact that gentamicin preferentially affects HC-I cells, which are specifically stimulated by SVIN [23]. Research has shown that if the VOR gain difference in the horizontal canal is relatively low following initial ITG treatment, the patient may experience poor control over vertigo [10].

Qian et al. [29] conducted an in vivo study combining two antibody markers, demonstrating that HC-I cells in all subdivisions of the utricular macule showed a greater capacity for gentamicin uptake than type II hair cells (HC-II). This observation aligns with previous findings indicating that HC-I cells are the primary targets of gentamicin and are more susceptible to its effects than HC-II cells [7]. Several reasons contribute to the higher accumulation of gentamicin in vivo in HC-I compared to HCII cells. First, the development of HC-I precedes that of HC-II cells [34]. This suggests that the mechanisms for gentamicin uptake are likely established in HC-I before HC-II. Second, gentamicin can penetrate hair cells either through the mechanoelectrical transduction channel on the stereocilia [35] or via apical endocytosis [36]. Given that HC-I hair bundles are more voluminous, they offer a greater number of mechanoelectrical transduction channels, resulting in a larger transduction current [37]. Third, HC-I cells in the cristae of the semicircular canals have higher negative resting potentials than HC-II cells [38]. This leads to a larger electrochemical gradient across the apical membrane, which is thought to provide an electromotive force for gentamicin entry into the HC [35]. In contrast, the utricular maculae are anatomically divided into striolar and extrastriolar regions based on the HC density and morphology. In the striola, HCs are less densely packed, and proportionally more HC-I cells are present; in contrast the number of both types of HC are approximately equivalent in the extrastriola [39].

Other analyses [26] have demonstrated a near-total loss of HC-I cells, with a 94% loss in the crista ampullaris of the lateral semicircular canal and an 86% loss in the utricular macula. In contrast, the loss of HC-II cells has been minimal, with a 4% loss in the crista ampullaris of the lateral semicircular canal and a 6% loss in the utricular macula. In a separate study, Hirvonen et al. [40] used a chinchilla model and filled the tympanic cavity with ITG. This resulted in a 57% reduction in the overall density of hair cells, including a 99% loss of HC-I and a 36% loss of HC-II cells.

In contrast, recordings from individual vestibular afferents in guinea pigs have demonstrated that low-frequency skull vibration (100 Hz) effectively stimulates the semicircular canal and otolith neurons that exhibit irregular resting discharge. These afferents are termed “irregular” due to the variability in the interval between action potentials when no stimulation is exerted, also known as the resting discharge. These irregular afferents innervate the amphora-shaped type I receptors located at the crest of the crista or at the striola of the otolithic maculae [9,10]. They respond with high sensitivity to 100-Hz vibration. Conversely, other afferent neurons, which primarily synapse on type II receptors on the crista slopes or in the extrastriolar area of the otolithic maculae, exhibit a regular resting discharge. However, they have a very poor or even non-existent response to vibration at clinically safe intensities [4].

To our knowledge, this is the first study to describe the association between decreased SPV and the likelihood of vertigo episodes in patients with MD who have been treated with ITG. Recovery in gain and a reduction in the SPV of SVIN are good predictors of new vertigo attacks after ITG administration. The observed preference of gentamicin for HC-I cells, coupled with the primary stimulation of these cells by SVIN, likely explains why the SPV of SVIN may be more effective than vHIT in detecting vestibular function recovery following ITG administration. However, additional studies are required to confirm this hypothesis.

HIGHLIGHTS

Article information Continued